pfizer (PFE.US) PARP inhibitor "talazoparib" approved for marketing.
On November 5th, the official website of the National Medical Products Administration (NMPA) showed that the application for the market approval of Pfizer's talazoparib capsules has been approved.
Express News | Pfizer targeted therapy innovative drug Tazenna approved in China
Pfizer's Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Is Pfizer Inc. (PFE) the Best Pharma Stock to Buy Right Now?
Pfizer | 10-Q: Q3 2024 Earnings Report
Why Nvidia Stock Is Less Important Than Sherwin-Williams for the Dow Jones Industrial Average